Catalogue

Background
CERT mediates the ATP-dependent ER-to-Golgi transfer of ceramide in a non-vesicular manner. The biosynthesis of lipids involves steps that occur in different intracellular compartments. The movement of lipids within these compartments is important in lipid-mediated signalling. Human CERT is identical to a splice variant of human Goodpasture antigen-binding protein (GPBP26).CERT contains a phosphoinositide-binding pleckstrin-homology (PH) domain (which targets CERT to the Golgi by binding phosphatidylinositol-4-phosphate (PtdIns4P)), a middle region, and a putative lipid-transfer-catalysing domain called START. CERT and CERTL can specifically extract ceramide from phospholipid bilayers in a START-domain-dependent manner. CERT interacts with ER membranes and specifically extracts ceramide. CERT catalyses both the specific extraction of ceramide from donor vesicles and its transfer to acceptor vesicles. CERT can associate with the Golgi in a PtdIns4P dependent manner. 

Synonyms: Goodpasture antigen-binding protein isoform 2, GPBP26, GPBP, Collagen type IV alpha-3-binding protein, StAR-related lipid transfer protein 11, StARD11, START domain-containing protein 11, COL4A3BP, STARD11

Source

Immunogen: Synthetic peptide derived from human CERTL protein

Product

Product Form: Unconjugated

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide

Concentration: See vial for concentration

Applications
For use with CERTL polyclonal antibodies (Cat. No. X2089P & X2379P).

Functional Analysis: Western Blotting

Positive Control: Ovary

Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Stability: See expiration date on vial

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.

References
1. Hanada K., Kumagai K., Yasuda S., Miura Y., Kawano M., Fukasawa M., Nishijima M.; Molecular machinery for non-vesicular trafficking of ceramide.; Nature 426:803-809(2003). 2. Raya A., Revert F., Navarro S., Saus J.; Characterization of a novel type of serine/threonine kinase that specifically phosphorylates the human goodpasture antigen.; J. Biol. Chem. 274:12642-12649(1999). 3. Raya A., Revert-Ros F., Martinez-Martinez P., Navarro S., Rosello E., Vieites B., Granero F., Forteza J., Saus J.; Goodpasture antigen-binding protein, the kinase that phosphorylates the Goodpasture antigen, is an alternatively spliced variant implicated in autoimmune pathogenesis.; J. Biol. Chem. 275:40392-40399(2000). 4. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Genome Res. 14:2121-2127(2004). 5. Ogi T., Yamamoto Y., Ohmori H.; Homo sapiens genomic sequence, containing DINB1 and GPBP gene.; Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases. 6. Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Cell 127:635-648(2006).

Protein Reference(s)

Database Name: UniProt

Accession Number: Q9Y5P4 (Human)

Species Accession: Human

Safety Datasheet(s) for this product: